AEON Biopharma, Inc. Class A (AEON)

Several events have impacted AEON Biopharma's stock price in the past six months. The company received positive feedback from the FDA on its ABP-450 biosimilar program. AEON reported its full-year 2025 financial results, including positive comparative analytical results and FDA feedback, and announced a $6.0 million PIPE and a note exchange that reduced debt. AEON Biopharma received additional notices of non-compliance from NYSE American LLC related to continued listing standards. John Bencich was appointed as the Chief Financial Officer, effective April 1, 2026. Shareholders have experienced substantial dilution in the past year, with a 140% increase in shares outstanding. Over the past 12 months, the stock has gained 89.6%, but from the beginning of 2026, AEON shares have decreased by 18.2% and are currently trading around $0.90.

AEON Biopharma's primary focus is on therapeutic applications of botulinum toxins, which generally exhibit different demand patterns compared to aesthetic uses. The demand for therapeutic botulinum toxin products is typically sustained by long-term clinical use and continuous treatment requirements, leading to a more consistent demand throughout the year rather than pronounced seasonal fluctuations. The U.S. therapeutic neurotoxin market is substantial, exceeding $3.0 billion annually, and is projected to grow steadily. The therapeutic market is driven by ongoing medical needs, suggesting less seasonality for AEON's target market.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection, a botulinum toxin complex, for debilitating medical conditions, particularly in the neurosciences market. The company aims to position ABP-450 as a biosimilar to BOTOX for therapeutic indications. AEON operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industries. Its core business revolves around the research and development of botulinum toxins for therapeutic use. The company's major product is ABP-450, which is the same botulinum toxin complex approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau. AEON is developing ABP-450 for various debilitating medical conditions, including cervical dystonia, chronic and episodic migraine, gastroparesis, and post-traumatic stress disorder. The manufacturing of ABP-450 is handled by Daewoong Pharmaceutical in a cGMP-compliant facility approved by the U.S. FDA, Health Canada, and the European Medicines Agency.

AEON Biopharma is headquartered in Irvine, California, United States. The company holds exclusive development and distribution rights for therapeutic indications of ABP-450 in key international territories, including the United States, Canada, the European Union, and the United Kingdom. ABP-450 is already approved as a biosimilar in India, Mexico, and the Philippines.

AEON Biopharma's brand reputation is largely tied to the progress and regulatory feedback concerning its lead product, ABP-450. The positive feedback from the FDA following the BPD Type 2a meeting in January 2026 is a significant positive for its scientific and regulatory reputation. The company highlights that ABP-450 is the same botulinum toxin approved in over 69 countries, including the U.S. for aesthetic use (Jeuveau), and is supported by a globally validated manufacturing platform, which contributes to a perception of reliability and established quality. However, the notices of non-compliance with NYSE American listing standards could potentially impact investor confidence and the company's financial reputation.

AEON Biopharma, Inc. has a mix of institutional and individual owners. As of May 6, 2026, there were 26 institutional owners holding a total of 2,474,690 shares. Major institutional shareholders include Dauntless Investment Group, LLC, Vanguard Group Inc, Geode Capital Management, Llc, XTX Topco Ltd, Blue Owl Capital Holdings LP, and Formidable Asset Management, LLC. Daewoong Co., Ltd. is a significant shareholder, holding 47.5% of the company, while individuals hold 17.1%. Institutional investors own 22.78% of AEON Biopharma's stock.